Table 2:
Cumulative incidence (%) of adrd by randomized group (3 study drugs) and other factors (1999 to 2017).
| Demographic | Alzheimer’s Disease (AD) | Other non-AD Dementias | All ADRD combined | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Events/Total (n/N) | 10-Year Rate/100 Persons (SE) | 18-Year Rate/100 Persons (SE)† | Events/Total | 10-Year Rate/100 Persons (SE) | 18-Year Rate/100 Persons (SE)† | Events/Total | 10-Year Rate/100 Persons (SE) | 18-Year Rate/100 Persons (SE)† | |
| All Patients | 3247/17158 | 16.3 (0.3) | 30.9 (0.5) | 7127/17158 | 35.4 (0.4) | 59.2 (0.5) | 7461/17158 | 37.5 (0.4) | 60.9 (0.5) |
| Randomized group | |||||||||
| Chlorthalidone | 1485/7907 | 16.3 (0.5) | 30.5 (0.7) | 3277/7907 | 35.6 (0.6) | 59.0 (0.7) | 3438/7907 | 37.8 (0.6) | 60.9 (0.7) |
| Amlodipine | 890/4636 | 16.6 (0.6) | 31.1 (1.0) | 1960/4636 | 35.7 (0.8) | 59.9 (1.0) | 2046/4636 | 37.7 (0.8) | 61.7 (1.0) |
| Lisinopril | 872/4615 | 16.0 (0.6) | 31.4 (1.0) | 1890/4615 | 35.0 (0.8) | 58.6 (1.0) | 1977/4615 | 37.0 (0.8) | 60.3 (1.0) |
| Age group (as of 1/1/1999) | |||||||||
| Age <70 | 843/6016 | 8.4 (0.4) | 21.7 (0.7) | 2114/6016 | 23.6 (0.6) | 48.1 (0.8) | 2208/6016 | 25.2 (0.6) | 49.8 (0.8) |
| Age 70–79 | 1738/8403 | 18.2 (0.5) | 34.5 (0.8) | 3627/8403 | 37.1 (0.6) | 63.0 (0.7) | 3796/8403 | 39.4 (0.6) | 64.8 (0.7) |
| Age 80+ | 666/2739 | 32.8 (1.2) | 48.5 (1.9) | 1386/2739 | 61.7 (1.2) | 77.4 (1.3) | 1457/2739 | 64.2 (1.2) | 79.5 (1.3) |
| Gender | |||||||||
| Male | 1154/7366 | 14.4 (0.5) | 27.4 (0.8) | 2749/7366 | 33.2 (0.6) | 56.5 (0.8) | 2870/7366 | 35.0 (0.6) | 57.9 (0.8) |
| Female | 2093/9792 | 17.7 (0.4) | 33.2 (0.7) | 4378/9792 | 37.0 (0.5) | 60.9 (0.6) | 4591/9792 | 39.3 (0.5) | 63.0 (0.6) |
| Race/ethnicity | |||||||||
| Black | 1228/5942 | 17.8 (0.6) | 33.8 (0.9) | 2667/5942 | 39.1 (0.7) | 63.6 (0.8) | 2772/5942 | 40.8 (0.7) | 65.1 (0.8) |
| Non-Black | 2019/11216 | 15.5 (0.4) | 29.4 (0.6) | 4460/11216 | 33.6 (0.5) | 56.8 (0.6) | 4689/11216 | 35.8 (0.5) | 58.7 (0.6) |
| Hispanic/Latino Ethnicity | |||||||||
| Hispanic | 689/3618 | 17.7 (0.7) | 26.2 (0.9) | 983/3618 | 24.1 (0.8) | 36.9 (1.0) | 1188/3618 | 30.2 (0.8) | 42.8 (1.0) |
| Non-Hispanic | 2542/13453 | 16.0 (0.4) | 32.6 (0.6) | 6104/13453 | 38.5 (0.5) | 65.2 (0.6) | 6233/13453 | 39.6 (0.5) | 66.0 (0.6) |
| Education level | |||||||||
| High school or less | 2273/11743 | 17.5 (0.4) | 31.7 (0.6) | 4900/11743 | 36.6 (0.5) | 59.7 (0.6) | 5151/11743 | 38.9 (0.5) | 61.8 (0.6) |
| More than high school | 728/4123 | 12.9 (0.6) | 28.9 (1.0) | 1708/4123 | 32.0 (0.8) | 58.1 (1.0) | 1764/4123 | 33.5 (0.8) | 59.2 (1.0) |
| Treatment with antihypertensive drugs prior to trial baseline | |||||||||
| Treated | 2933/15554 | 16.3 (0.3) | 30.9 (0.5) | 6476/15554 | 35.6 (0.4) | 59.5 (0.5) | 6778/15554 | 37.7 (0.4) | 61.3 (0.5) |
| Untreated | 314/1604 | 16.4 (1.0) | 31.1 (1.6) | 651/1604 | 34.1 (1.3) | 56.0 (1.6) | 683/1604 | 35.6 (1.3) | 57.8 (1.6) |
| Aspirin use (as of 1/1/1999) | |||||||||
| Yes | 1133/6347 | 14.9 (0.5) | 31.1 (0.9) | 2650/6347 | 34.7 (0.7) | 61.5 (0.9) | 2752/6347 | 36.4 (0.7) | 63.0 (0.8) |
| No | 2079/10647 | 17.1 (0.4) | 30.8 (0.6) | 4416/10647 | 35.9 (0.5) | 57.9 (0.6) | 4644/10647 | 38.2 (0.5) | 59.8 (0.6) |
| Women taking estrogen at trial baseline | |||||||||
| Yes | 301/1433 | 15.1 (1.0) | 29.7 (1.5) | 678/1433 | 33.9 (1.3) | 60.3 (1.6) | 697/1433 | 35.9 (1.3) | 61.2 (1.6) |
| No | 1754/8183 | 18.2 (0.5) | 33.8 (0.7) | 3629/8183 | 37.6 (0.6) | 61.1 (0.7) | 3817/8183 | 40.0 (0.6) | 63.3 (0.7) |
| HDL cholesterol <35 mg/dl (as of 1/1/1999) | |||||||||
| Yes | 457/2764 | 13.9 (0.8) | 29.9 (1.4) | 1029/2764 | 32.4 (1.0) | 56.7 (1.3) | 1080/2764 | 34.4 (1.0) | 58.2 (1.3) |
| No | 2790/14394 | 16.7 (0.4) | 31.1 (0.5) | 6098/14394 | 36.0 (0.4) | 59.6 (0.5) | 6381/14394 | 38.1 (0.4) | 61.4 (0.5) |
| Cigarette smoking at trial baseline | |||||||||
| Never smoker | 1650/7562 | 18.0 (0.5) | 32.7 (0.7) | 3372/7562 | 36.3 (0.6) | 59.7 (0.7) | 3539/7562 | 38.7 (0.6) | 61.7 (0.7) |
| Current smoker | 422/2811 | 14.1 (0.8) | 29.7 (1.4) | 1017/2811 | 35.0 (1.1) | 57.5 (1.4) | 1068/2811 | 36.8 (1.1) | 59.7 (1.4) |
| Former Smoker | 1175/6784 | 15.2 (0.5) | 29.3 (0.8) | 2737/6784 | 34.7 (0.7) | 59.1 (0.8) | 2853/6784 | 36.5 (0.7) | 60.5 (0.8) |
| Diabetes classification (as of 1/1/1999) | |||||||||
| Diabetes | 1317/7012 | 17.1 (0.5) | 33.2 (0.9) | 2963/7012 | 38.5 (0.7) | 63.1 (0.8) | 3109/7012 | 40.7 (0.7) | 65.0 (0.8) |
| Non-diabetes | 1689/8900 | 15.5 (0.4) | 29.4 (0.7) | 3633/8900 | 32.8 (0.5) | 56.3 (0.7) | 3798/8900 | 34.9 (0.6) | 58.0 (0.7) |
| History of Coronary Heart Disease (CHD) (as of 1/1/1999) | |||||||||
| Yes | 842/4792 | 16.3 (0.6) | 31.4 (1.0) | 1966/4792 | 36.6 (0.8) | 61.2 (1.0) | 2053/4792 | 38.7 (0.8) | 63.0 (1.0) |
| No | 2405/12366 | 16.3 (0.4) | 30.8 (0.6) | 5161/12366 | 35.0 (0.5) | 58.4 (0.6) | 5408/12366 | 37.1 (0.5) | 60.2 (0.6) |
| Atherosclerotic Cardiovascular Disease (ASCVD) at trial baseline | |||||||||
| Yes | 1795/9375 | 17.4 (0.5) | 31.9 (0.7) | 4015/9375 | 37.8 (0.6) | 61.7 (0.7) | 4184/9375 | 39.7 (0.6) | 63.2 (0.7) |
| No | 1452/7783 | 15.1 (0.5) | 29.7 (0.7) | 3112/7783 | 32.7 (0.6) | 56.3 (0.7) | 3277/7783 | 35.0 (0.6) | 58.3 (0.7) |
| History of Myocardial Infarction (MI) or stroke (as of 1/1/1999) | |||||||||
| Yes | 825/4606 | 18.5 (0.7) | 32.6 (1.1) | 1985/4606 | 42.2 (0.8) | 65.3 (1.0) | 2059/4606 | 44.1 (0.8) | 66.6 (1.0) |
| No | 2422/12552 | 15.6 (0.4) | 30.3 (0.6) | 5142/12552 | 33.2 (0.5) | 57.2 (0.6) | 5402/12552 | 35.3 (0.5) | 59.1 (0.6) |
| History of Coronary Artery Bypass Graft (CABG) (as of 1/1/1999) | |||||||||
| Yes | 442/2652 | 15.2 (0.8) | 32.6 (1.5) | 1100/2652 | 38.0 (1.1) | 64.6 (1.4) | 1131/2652 | 39.3 (1.1) | 65.7 (1.4) |
| No | 2805/14506 | 16.5 (0.4) | 30.8 (0.5) | 6027/14506 | 35.0 (0.4) | 58.3 (0.5) | 6330/14506 | 37.2 (0.4) | 60.2 (0.5) |
| Other ASCVD at trial baseline | |||||||||
| Yes | 839/4516 | 17.0 (0.6) | 31.1 (1.0) | 1950/4516 | 37.9 (0.8) | 62.0 (1.0) | 2023/4516 | 39.7 (0.8) | 63.4 (1.0) |
| No | 2408/12642 | 16.1 (0.4) | 30.8 (0.6) | 5177/12642 | 34.6 (0.5) | 58.2 (0.6) | 5438/12642 | 36.8 (0.5) | 60.1 (0.6) |
| Major ST segment depression (as of 1/1/1999) | |||||||||
| Yes | 241/1374 | 15.3 (1.1) | 29.8 (1.8) | 553/1374 | 36.5 (1.5) | 58.1 (1.8) | 576/1374 | 38.2 (1.5) | 59.7 (1.8) |
| No | 2996/15732 | 16.4 (0.3) | 31.0 (0.5) | 6550/15732 | 35.4 (0.4) | 59.2 (0.5) | 6861/15732 | 37.5 (0.4) | 61.0 (0.5) |
| Left Ventricular Hypertrophy (LVH) by Minnesota code (as of 1/1/1999) | |||||||||
| Hard LVH | 115/658 | 19.2 (1.9) | 33.3 (3.1) | 281/658 | 46.7 (2.3) | 63.2 (2.8) | 295/658 | 48.5 (2.3) | 65.1 (2.7) |
| No/Soft LVH | 2770/14632 | 16.0 (0.3) | 30.7 (0.5) | 6151/14632 | 35.2 (0.4) | 59.7 (0.5) | 6421/14632 | 37.1 (0.4) | 61.3 (0.5) |
| Lipid Lowering Trial (LLT) participant | |||||||||
| Yes | 775/4181 | 15.7 (0.6) | 28.6 (1.0) | 1699/4181 | 33.1 (0.8) | 56.7 (1.0) | 1789/4181 | 35.5 (0.8) | 58.8 (1.0) |
| No | 2472/12977 | 16.5 (0.4) | 31.7 (0.6) | 5428/12977 | 36.2 (0.5) | 60.0 (0.6) | 5672/12977 | 38.2 (0.5) | 61.6 (0.6) |
| Obesity (BMI ≥ 30 kg/m2) at trial baseline | |||||||||
| Yes | 1193/6821 | 13.7 (0.5) | 29.7 (0.8) | 2855/6821 | 34.0 (0.6) | 60.3 (0.8) | 2954/6821 | 35.5 (0.6) | 61.6 (0.8) |
| No | 2054/10337 | 18.1 (0.4) | 31.7 (0.6) | 4272/10337 | 36.4 (0.5) | 58.4 (0.7) | 4507/10337 | 38.9 (0.5) | 60.4 (0.6) |
Abbreviations: ADRD:Alzheimer’s Disease and Related Dementias; SE:Standard Error
Note:
†
18-year time to event includes events occurring up to, but not including year 19 (e.g. throughout the year 2017)